Navigation Links
First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder

BTX-A also significantly improved all secondary endpoints, including measures of bladder filling and pressure; urination frequency, urgency urinary incontinence episodes, and urgency (at 4 weeks only); and QoL. All these improvements were significantly greater than with placebo vs. baseline.

The extension study lasting until week 24 suggested that most of these beneficial effects of BTX-A were maintained for at least 24 weeks. At baseline, 81% of patients in the BTX-A group were experiencing urgent urinary incontinence daily, but urinary frequency normalized in 57% at 4 weeks, and 36% maintained this benefit at 24 weeks; further, 50% were continent at follow-up, and the improvement lasted 24 weeks. Complete resolution of detrusor overactivity was observed in 44% of BTX-A patients at 4 weeks, though this dropped to 25% by 24 weeks.

Quality of life was assessed using the IIQ-7 and UDI-6 and was significantly better in the BTX-A group compared with placebo at both 4 and 12 weeks post-injections.

Treatment with BTX-A was well tolerated and there were no major complications. Six patients in the BTX-A group had symptomatic post void residual (PVR) at follow-up requiring clean intermittent self catheterization (CISC). Seven patients developed symptomatic urinary tract infection, six of whom were performing CISC. Mr. Sahai's and Mr. Dasgupta's co-researcher was Mohammad S. Khan, FRCS (urol) FEBU, consultant urologist at Guy's Hospital, London. BTX-A is not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of any form of OAB, nor is it currently approved for this use by regulatory agencies in Europe. This research was funded by Allergan, Inc and through a project grant from the British Urological Foundation.

    (1) National Diabetes Information Clearinghouse, a service of the National

        Institute of Diabetes and Digestive and Kidney Disease (DIDDK), NIH,

        




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/20/2014)...   Ventana Medical Systems, Inc.  (Ventana), a ... its VENTANA System for Primary Diagnosis 1 ... for routine pathology, including primary diagnosis with human ... software coupled with either the VENTANA iScan Coreo ... automated digital slide creation, case management and computer ...
(Date:8/20/2014)... LYNDHURST, N.J. , Aug. 20, 2014  Amerigen ... Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA ... Mecobalamin 0.5 mg Tablets into the ... of a marketing and distribution agreement with Sinochem ... product at its US FDA approved and China ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 According ... filed on August 7 in the multicounty litigation (MCL) ... (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), ... MCL have been dismissed without prejudice. The cases enumerated ... process of being resolved.” The Rottenstein Law Group LLP, ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
(Date:8/20/2014)... Pittsburgh, PA (PRWEB) August 20, 2014 ... to clean the mouth in an optimal manner without ... an inventor from Vacaville, Calif. , The patent-pending DR. ... the tongue and teeth thoroughly. It promotes good oral ... to use two different devices. Convenient, compact, affordable, eco-friendly ...
(Date:8/20/2014)... Tumour Research has been chosen by Plymouth University to ... launched in April 2009 to raise awareness of, and ... outcomes for brain tumour patients. , A range of ... funds for the charity, and members of staff and ... encouraged to donate, fundraise and volunteer. The involvement of ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2
... Preventative Services Task Force,s (USPSTF) recommendation to no longer ... has begun to negatively affect the number of yearly ... the benefits of early detection. After the USPSTF delivered ... of Colorado saw a significant drop in mammograms in ...
... Mayo Clinic researchers have discovered two mutations responsible for ... ago. The researchers say their study -- appearing in ... neural pathway that may help understand a variety of ... now because of Next Generation genomic sequencing technology," says ...
... bursts of sleep in infants are linked with growth spurts, new ... daily sleep records for their infants (14 girls, nine boys), who ... researchers analyzed the total of 5,798 daily sleep records and also ... sleep, with the amount of sleep over a 24-hour period increasing ...
... can be quite jarring for a parent or caregiver to ... child roaming around the backseat free of their safety restraints. ... researchers reveals that most children who first unbuckle were age ... vehicle is in motionputting them at a 3.5-fold increased risk ...
... -- A drug commonly used to treat kidney cancer may ... study published in the May issue of the Journal ... the action of mammalian target of rapamycin (mTOR), a protein ... used to treat advanced renal cell carcinoma. But researchers ...
... Medical costs for children and teens with diabetes are six ... States, a new study finds. Researchers from the U.S. ... made in 2007 for nearly 50,000 youth aged 19 and ... youth with diabetes were $9,061, compared with $1,468 for those ...
Cached Medicine News:Health News:New studies show negative effects from revised mammography recommendation for women, ages 40-49 2Health News:Mayo Clinic finds new genetic cause of neurodegeneration 2Health News:Extra Sleep in Infants Seems to Signal Growth Spurts 2Health News:Little fingers, big trouble: Yale study sheds light on child self-unbuckling 2Health News:Renal cancer drug temsirolimus shows promise against mesothelioma 2
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
5L...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
Medicine Products: